Arsenic exposure alters purine metabolism in rats, mice, and humans

Arsenic Exposure and Health Effects V

Volumn , Issue , 2003, Pages 135-145

  Del Razo, Luz María ^a   García Montalvo, Eliud A ^a   Valenzuela, Olga L ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Arsenic; Arsenic biomarker; Purine metabolism; Uric acid; Xanthine oxidase

Indexed keywords

ARSENIC; BIOCHEMISTRY; MAMMALS; ORGANIC ACIDS; PHOSPHOLIPIDS; PHYSIOLOGY; POTABLE WATER; RATS;

ACTIVE INTERMEDIATES; ADVERSE HEALTH EFFECTS; BIOLOGICAL SAMPLES; CARBOHYDRATE METABOLISM; CONTAMINATED DRINKING WATER; METABOLIC DISORDERS; URIC ACIDS; XANTHINE OXIDASE;

METABOLISM;

EID: 84942580535     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451441-7/50011-7     Document Type: Chapter

References (28)

1. Abernathy C.O., Liu Y.P., Longfellow D., Aposhian H.V., Beck B., Fowler B., Goyer R., Menzer R., Rossman T., Thompson C., Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect. 1999, 107:593-597.
2. Alsabti E. Serum xanthine oxidase in bladder carcinoma. Urol. Int. 1979, 34:233-236.
3. Alsabti E. Serum xanthine oxidase in breast carcinoma. Neoplasma 1980, 27:95-99.
4. Barber M.J., Siegel L.M. Electron paramagnetic resonance and potentiometric studies of arsenite interaction with the molybdenum centers of xanthine oxidase, xanthine dehydrogenase, and aldehyde oxidase: a specific stabilization of the molybdenum(V) oxidation state. Biochemistry 1983, 22:618-624.
5. Bray R.C., Barber M.J., Dalton H., Lowe D.J., Coughlan M.P. Iron-sulphur systems in some isolated multi-component oxidative enzymes. Biochem. Soc. Trans. 1975, 3:479-482.
6. Coughlan M.P., Rajagopalan K.V., Handler P. The role of molybdenum in xanthine oxidase and related enzymes. Reactivity with cyanide, arsenite, and methanol. J. Biol. Chem. 1969, 244:2658-2663.
7. Davis M.D., Olson J.S., Palmer G. Charge transfer complexes between pteridine substrates and the active center molybdenum of xanthine oxidase. J. Biol. Chem. 1982, 257:14730-14737.
8. Del Razo L.M., Styblo M., Cullen W.R., Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 2001, 174:282-293.
9. Del Razo L.M., Quintanilla-Vega B., Brambila-Colombres E., Calderon-Aranda E.S., Manno M., Albores A. Stress proteins induced by arsenic. Toxicol. Appl. Pharmacol. 2001, 177:132-148.
10. DOGM Diario Oficial del Gobierno Mexicano. Norma oficial Mexicana NOM-062-ZOO-1999. "Especificationes técnicas para la producción, cuidado y uso de los animales de laboratorio", In Spanish 2001.
11. Durak I., Perk H., Kavutcu M., Canbolat O., Akyol O., Beduk Y. Adenosine deaminase, 5' nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in cancerous and noncancerous human bladder tissues. Free Radic. Biol. Med. 1994, 16:825-831.
12. George G.N., Bray R.C. Reaction of arsenite ions with the molybdenum center of milk xanthine oxidase. Biochemistry 1983, 22:1013-1021.
13. Gregus Z., Nemeti B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 2002, 70:13-19.
14. Hille R., Stewart R.C., Fee J.A., Massey V. The interaction of arsenite with xanthine oxidase. J. Biol. Chem. 1983, 258:4849-4856.
15. Jauge P., Del Razo L.M. Urinary uric acid determination by reversed-phase high pressure liquid chromatography. J. Liquid Chromatogr. 1983, 6:845-860.
16. Jauge P., Del Razo L.M. Uric acid levels in plasma and urine in rats chronically exposed to arsenic As(III) and As(V). Toxicol. Lett. 1985, 26:31-35.
17. Kline P.C., Schramm V.L. Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity. Biochemistry 1992, 31:5964-5973.
18. Kline P.C., Schramm V.L. Purine nucleoside phosphorylase. Catalytic mechanism an transition-state analysis of the arsenolysis reaction. Biochemistry 1993, 32:13212-13219.
19. Knowles F.C., Benson A.A. The enzyme inhibitory form of inorganic arsenic. Z. Gesamte Hyg. 1984, 30:625-626.
20. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 1991, 3:45-81.
21. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
22. Radabaugh T.R., Sampayo-Reyes A., Zakharyan R.A., Aposhian H.V. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 2002, 15:692-698.
23. Stirpe F., Ravaioli M., Battelli M.G., Musiani S., Grazi G.L. Xanthine oxidoreductase activity in human liver disease. Am. J. Gastroenterol. 2002, 8:2079-2085.
24. Styblo M., Drobná Z., Jaspers L., Lin S., Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 2002, 110(Suppl. 5):767-771.
25. Thomas D.J., Styblo M., Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 2001, 176:127-144.
26. Vaidya S.M., Kamlakar P.L., Kamble S.M. Molybdenum, xanthine oxidase and riboflavin levels in tamoxifen treated postmenopausal women with breast cancer. Indian J. Med. Sci. 1998, 52:244-247.
27. Waring W.S., Webb D.J., Maxwell S.R. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J. Cardiovasc. Pharmacol. 2001, 38:365-371.
28. Welch A.H., Helsel D.R., Focazio M.J., Watkins S.A. Arsenic in the ground water supplies of the United States. Arsenic Exposure and Health Effects 1999, 9-17. Elsevier, Amsterdam. W.R. Chappell, C.O. Abernathy, R.L. Calderon (Eds.).